Polson, J. & Lee, W. M. AASLD position paper: The management of acute liver failure. Hepatology 41, 1179–1197 (2005).
Mochida, S. et al. Diagnostic criteria of acute liver failure: A report by the intractable Hepato-Biliary diseases study group of Japan. Hepatol. Res. 41, 805–812 (2011).
Antoniades, C. G., Berry, P. A., Wendon, J. A. & Vergani, D. The importance of immune dysfunction in determining outcome in acute liver failure. J. Hepatol. 49, 845–861 (2008).
Zheng, S.-J. et al. Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure. World J. Gastroenterol. 20, 2403–2411 (2014).
Papatheodoridis, G. V. et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 57, 500–506 (2008).
Papatheodoridis, G. V. et al. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J. Clin. Gastroenterol. 44, e87-95 (2010).
Thulin, P. et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 34, 367–378 (2014).
Diab, D. L. et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin. Gastroenterol. Hepatol. 6, 1249–1254 (2008).
Tsutsui, M. et al. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J. Clin. Gastroenterol. 44, 440–447 (2010).
Bechmann, L. P. et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J. Hepatol. 53, 639–647 (2010).
Macdonald, S. et al. Cell death markers in patients with cirrhosis and acute decompensation. Hepatology 67, 989–1002 (2018).
Martin, S. J., Henry, C. M. & Cullen, S. P. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol. Cell 46, 387–397 (2012).
Shashaty, M. G. S. et al. Plasma levels of receptor interacting protein kinase-3 (RIP3), an essential mediator of necroptosis, are associated with acute kidney injury in critically ill trauma patients. Shock 46, 139–143 (2016).
Vergara, G. A., Eugenio, G. C., Malheiros, S. M. F., Victor, E. da S. & Weinlich, R. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping. J. Neurooncol. 147, 587–594 (2020).
Kondo, T. et al. The role of RIPK1 mediated cell death in acute on chronic liver failure. Cell Death Dis. 13, 5 (2021).
Böhm, F., Köhler, U. A., Speicher, T. & Werner, S. Regulation of liver regeneration by growth factors and cytokines. EMBO Mol. Med. 2, 294–305 (2010).
Nejak-Bowen, K., Orr, A., Bowen, W. C. J. & Michalopoulos, G. K. Conditional genetic elimination of hepatocyte growth factor in mice compromises liver regeneration after partial hepatectomy. PLoS ONE 8, e59836 (2013).
Shiota, G., Okano, J., Kawasaki, H., Kawamoto, T. & Nakamura, T. Serum hepatocyte growth factor levels in liver diseases: Clinical implications. Hepatology 21, 106–112 (1995).
Fujiwara, K. et al. Severe and fulminant hepatitis of indeterminate etiology in a Japanese center. Hepatol. Res. 45, E141–E149 (2015).
Blei, A. T. & Córdoba, J. Hepatic encephalopathy. Am. J. Gastroenterol. 96, 1968–1976 (2001).
Alvarez, F. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31, 929–938 (1999).
Fujiwara, K., Hida, S., Yasui, S., Yokosuka, O. & Oda, S. Corticosteroid might reduce serum levels of pro-inflammatory cytokines in fulminant hepatitis: A case series. Hepatol. Res. 48, 106–112 (2018).
Kondo, T. et al. Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. PLoS ONE 17, e0261619 (2022).
Jochum, C. et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 80, 235–240 (2009).
Bird, T. G. et al. TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. Sci. Transl. Med. 10, eaan1230 (2018).
Imanishi, T. et al. RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8. Sci. Adv. 9, eadd6097 (2023).
Chen, J. et al. Early diagnostic biomarkers of sepsis for patients with acute-on-chronic liver failure: A multicenter study. Infect. Dis. Ther. 10, 281–290 (2021).
Jalan, R. et al. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: A prospective cohort study. Crit. care 16, R227 (2012).
Hernaez, R., Solà, E., Moreau, R. & Ginès, P. Acute-on-chronic liver failure: An update. Gut 66, 541–553 (2017).
Redeker, A. G., Schweitzer, I. L. & Yamahiro, H. S. Letter: Randomization of corticosteroid therapy in fulminant hepatitis. N. Engl. J. Med. 294, 728–729 (1976).
Gregory, P. B., Knauer, C. M., Kempson, R. L. & Miller, R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N. Engl. J. Med. 294, 681–687 (1976).
Fujiwara, K. et al. Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol. Res. 44, 491–501 (2014).
Anastasiou, O. E. et al. Corticosteroid therapy improves the outcome of autoimmune hepatitis-induced acute liver failure. Digestion 98, 104–111 (2018).
Oketani, M. et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009. Hepatol. Res. 43, 97–105 (2013).
Morgan, M. J. & Kim, Y.-S. Roles of RIPK3 in necroptosis, cell signaling, and disease. Exp. Mol. Med. 54, 1695–1704 (2022).
Bertheloot, D., Latz, E. & Franklin, B. S. Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. Cell. Mol. Immunol. 18, 1106–1121 (2021).
Moriwaki, K. & Chan, F.K.-M. The inflammatory signal adaptor RIPK3: Functions beyond necroptosis. Int. Rev. Cell Mol. Biol. 328, 253–275 (2017).
Tsubouchi, H. et al. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology 9, 875–881 (1989).
Tsubouchi, H. et al. Prediction of outcome in fulminant hepatic failure by serum human hepatocyte growth factor. Lancet 340, 307 (1992).
Soeters, P. B., Wolfe, R. R. & Shenkin, A. Hypoalbuminemia: Pathogenesis and clinical significance. JPEN. J. Parenter. Enteral Nutr. 43, 181–193 (2019).
Wan, S.-Z., Nie, Y., Zhang, Y., Liu, C. & Zhu, X. Assessing the prognostic performance of the child-pugh, model for end-stage liver disease, and albumin-bilirubin scores in patients with decompensated cirrhosis: A large Asian cohort from gastroenterology department. Dis. Markers 2020, 5193028 (2020).
Gottlieb, A. et al. How to define acute liver failure patients with pre-existing liver disease without signs of cirrhosis. Dig. Dis. 37, 147–154 (2019).
Canbay, A. et al. Acute liver failure: A life-threatening disease. Dtsch. Arztebl. Int. 108, 714–720 (2011).